To evaluate the clinical efficacy of Runfei Zhike Prescription from Peking University Third Hospital in the treatment of patients with cough following Corona Virus Disease 2019(COVID-19) infection.Methods:From December 15，2022 to January 5，2023，108 patients with cough following COVID-19 infection in the Department of Traditional Chinese Medicine，Peking University Third Hospital were retrospectively collected，including 68 cases in the observation group and 40 cases in the control group.The observation group was treated with Runfei Zhike Prescription，and the control group included patients with cough following COVID-19 infection who were not treated with any traditional Chinese medicine(TCM)，but there may be symptomatic treatment with Western medicine.The basic data，TCM syndromes，and medication of the patients were collected.The time of body temperature normalization，nucleic acid negative conversion，and clinical efficacy were compared between the two groups.Results:There was no statistical significance in the time of body temperature normalization and nucleic acid negative conversion between the two groups(P=0.892，P=0.967).The clinical cure rate and the total effective rate were 52.9%(36/68) and 88.2%(60/68) in the observation group，which were significantly better than the clinical cure rate of 12.5%(5/40) and the total effective rate of 47.5%(19/40) in the control group(P<0.01).Conclusion:Runfei Zhike Prescription from Peking University Third Hospital can improve the cough of patients following COVID-19 infection and enhance the effective rate and cure rate of TCM in treating cough following COVID-19 infection.